TABLE OF CONTENTS
1 INTRODUCTION 71
1.1 OBJECTIVES OF THE STUDY 71
1.2 MARKET DEFINITION 71
1.3 OVERVIEW OF THE EUROPE RADIOPHARMACEUTICALS MARKET 71
1.4 LIMITATIONS 73
1.5 MARKETS COVERED 73
2 MARKET SEGMENTATION 76
2.1 MARKETS COVERED 76
2.2 GEOGRAPHICAL SCOPE 77
2.3 YEARS CONSIDERED FOR THE STUDY 78
2.4 CURRENCY AND PRICING 78
2.5 DBMR TRIPOD DATA VALIDATION MODEL 79
2.6 MULTIVARIATE MODELLING 82
2.7 PRODUCT TYPE LIFELINE CURVE 82
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 83
2.9 DBMR MARKET POSITION GRID 84
2.10 MARKET TESTING TYPE COVERAGE GRID 86
2.11 VENDOR SHARE ANALYSIS 87
2.12 SECONDARY SOURCES 88
2.13 ASSUMPTIONS 88
3 EXECUTIVE SUMMARY 89
4 PREMIUM INSIGHTS 92
4.1 PESTEL ANALYSIS 93
4.2 PORTERS FIVE FORCES 94
4.3 PIPELINE ANALYSIS 95
4.4 PATENT ANALYSIS 96
4.5 DRUG TREATMENT RATE BY MATURED MARKETS 102
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 103
4.7 PATIENT FLOW DIAGRAM 104
4.8 KEY PRICING STRATEGIES 104
4.9 KEY PATIENT ENROLLMENT STRATEGIES 105
5 LIST OF CYCLOTRONS 107
5.1 EUROPE 107
6 REGULATORY SCENARIO 119
6.1 EUROPE 119
7 MARKET OVERVIEW 120
7.1 DRIVERS 122
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE 122
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS 122
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES 123
7.2 RESTRAINTS 123
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS 123
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS 123
7.3 OPPORTUNITIES 124
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS 124
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION 124
7.4 CHALLENGES 125
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 125
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE 126
8 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE 127
8.1 OVERVIEW 128
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS 131
8.2.1 PET RADIOPHARMACEUTICALS 132
8.2.1.1 F-18 132
8.2.1.2 RU-82 132
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS 132
8.2.2 SPECT RADIOPHARMACEUTICALS 133
8.2.2.1 TECHNETIUM-99M 133
8.2.2.2 GALLIUM-67 133
8.2.2.3 IODINE-123 133
8.2.2.4 THALLIUM-201 133
8.2.2.5 OTHER SPECT ISOTOPES 133
8.3 THERAPEUTIC RADIOPHARMACEUTICALS 134
8.3.1 BRACHYTHERAPY ISOTOPES 135
8.3.1.1 IODINE-125 135
8.3.1.2 PALLADIUM-103 135
8.3.1.3 CESIUM-131 135
8.3.1.4 IRIDIUM-192 136
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES 136
8.3.2 BETA EMITTERS 136
8.3.2.1 IODINE-131 136
8.3.2.2 LUTHETIUM-177 136
8.3.2.3 SAMARIUM-153 136
8.3.2.4 YTTRIUM-90 136
8.3.2.5 RHENIUM-186 137
8.3.2.6 OTHER BETA EMITTERS 137
8.3.3 ALPHA EMITTERS 137
8.3.3.1 RA-223 137
8.3.3.2 OTHERS 137
9 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION 138
9.1 OVERVIEW 139
9.2 DIAGNOSTIC 142
9.2.1 PET 143
9.2.1.1 ONCOLOGY 143
9.2.1.2 CARDIOLOGY 143
9.2.1.3 NEUROLOGY 143
9.2.1.4 OTHER PET APPLICATION 143
9.2.2 SPECT 144
9.2.2.1 CARDIOLOGY 144
9.2.2.2 BONE SCANS 144
9.2.2.3 THYROID APPLICATIONS 144
9.2.2.4 PULMONARY SCANS 144
9.2.2.5 OTHER SPECT APPLICATION 144
9.3 THERAPEUTIC 145
9.3.1 THYROID INDICATIONS 146
9.3.2 BONE METASTASIS 146
9.3.3 LYMPHOMA 146
9.3.4 ENDOCRINE TUMORS 146
9.3.5 OTHER INDICATIONS 146
10 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE 147
10.1 OVERVIEW 148
10.2 NUCLEAR REACTORS 151
10.3 CYCLOTRONS 152
11 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER 153
11.1 OVERVIEW 154
11.2 HOSPITALS 157
11.3 DIAGNOSTIC CENTERS 157
11.4 CANCER RESEARCH INSTITUTES 158
11.5 AMBULATORY SURGICAL CENTERS 159
11.6 OTHERS 160
12 EUROPE RADIOPHARMACEUTICALS MARKET, BY REGION 161
12.1 EUROPE 162
12.1.1 GERMANY 173
12.1.2 U.K. 180
12.1.3 FRANCE 187
12.1.4 ITALY 194
12.1.5 SPAIN 201
12.1.6 BELGIUM 208
12.1.7 POLAND 215
12.1.8 RUSSIA 222
12.1.9 NORWAY 229
12.1.10 TURKEY 236
12.1.11 AUSTRIA 242
12.1.12 IRELAND 249
12.1.13 HUNGARY 256
12.1.14 NETHERLANDS 263
12.1.15 SWITZERLAND 270
12.1.16 REST OF EUROPE 277
13 EUROPE RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 278
13.1 COMPANY SHARE ANALYSIS: EUROPE 278
14 SWOT ANALYSIS 279
15 COMPANY PROFILE 280
15.1 CARDINAL HEALTH 280
15.1.1 COMPANY SNAPSHOT 280
15.1.2 REVENUE ANALYSIS 280
15.1.3 COMPANY SHARE ANALYSIS 281
15.1.4 PRODUCT PORTFOLIO 281
15.1.5 RECENT DEVELOPMENT 282
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY 283
15.2.1 COMPANY SNAPSHOT 283
15.2.2 REVENUE ANALYSIS 283
15.2.3 COMPANY SHARE ANALYSIS 284
15.2.4 PRODUCT PORTFOLIO 284
15.2.5 RECENT DEVELOPMENT 284
15.3 LANTHEUS 285
15.3.1 COMPANY SNAPSHOT 285
15.3.2 REVENUE ANALYSIS 285
15.3.3 COMPANY SHARE ANALYSIS 286
15.3.4 PRODUCT PORTFOLIO 286
15.3.5 RECENT DEVELOPMENT 286
15.4 CURIUM 287
15.4.1 COMPANY SNAPSHOT 287
15.4.2 COMPANY SHARE ANALYSIS 287
15.4.3 PRODUCT PORTFOLIO 288
15.4.4 RECENT DEVELOPMENT 288
15.5 GENERAL ELECTRIC COMPANY 289
15.5.1 COMPANY SNAPSHOT 289
15.5.2 REVENUE ANALYSIS 289
15.5.3 COMPANY SHARE ANALYSIS 290
15.5.4 PRODUCT PORTFOLIO 290
15.5.5 RECENT DEVELOPMENT 290
15.6 BRACCO 291
15.6.1 COMPANY SNAPSHOT 291
15.6.2 PRODUCT PORTFOLIO 291
15.6.3 RECENT DEVELOPMENT 291
15.7 BWX TECHNOLOGIES. INC. 292
15.7.1 COMPANY SNAPSHOT 292
15.7.2 REVENUE ANALYSIS 292
15.7.3 PRODUCT PORTFOLIO 293
15.7.4 RECENT DEVELOPMENT 293
15.8 CHINA ISOTOPE & RADIATION CORPORATION 294
15.8.1 COMPANY SNAPSHOT 294
15.8.2 REVENUE ANALYSIS 294
15.8.3 PRODUCT PORTFOLIO 295
15.8.4 RECENT DEVELOPMENT 295
15.9 COQUI RADIOPHARMACEUTICALS CORP. 296
15.9.1 COMPANY SNAPSHOT 296
15.9.2 PRODUCT PORTFOLIO 296
15.9.3 RECENT DEVELOPMENT 296
15.10 ECKERT & ZIEGLER 297
15.10.1 COMPANY SNAPSHOT 297
15.10.2 REVENUE ANALYSIS 297
15.10.3 PRODUCT PORTFOLIO 298
15.10.4 RECENT DEVELOPMENT 298
15.11 ECZACIBAI-MONROL 299
15.11.1 COMPANY SNAPSHOT 299
15.11.2 PRODUCT PORTFOLIO 299
15.11.3 RECENT DEVELOPMENT 299
15.12 EVERGREEN THERAGNOSTICS, INC. 300
15.12.1 COMPANY SNAPSHOT 300
15.12.2 PRODUCT PORTFOLIO 300
15.12.3 RECENT DEVELOPMENT 300
15.13 EUROPE MEDICAL SOLUTIONS 301
15.13.1 COMPANY SNAPSHOT 301
15.13.2 PRODUCT PORTFOLIO 301
15.13.3 RECENT DEVELOPMENT 301
15.14 IBA WORLDWIDE 302
15.14.1 COMPANY SNAPSHOT 302
15.14.2 REVENUE ANALYSIS 302
15.14.3 PRODUCT PORTFOLIO 303
15.14.4 RECENT DEVELOPMENT 303
15.15 INSTITUTE OF ISOTOPES 304
15.15.1 COMPANY SNAPSHOT 304
15.15.2 PRODUCT PORTFOLIO 304
15.15.3 RECENT DEVELOPMENT 304
15.16 ISOTOPE JSC 305
15.16.1 COMPANY SNAPSHOT 305
15.16.2 PRODUCT PORTFOLIO 305
15.16.3 RECENT DEVELOPMENT 305
15.17 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY 306
15.17.1 COMPANY SNAPSHOT 306
15.17.2 REVENUE ANALYSIS 306
15.17.3 PRODUCT PORTFOLIO 307
15.17.4 RECENT DEVELOPMENT 307
15.18 NTP 308
15.18.1 COMPANY SNAPSHOT 308
15.18.2 PRODUCT PORTFOLIO 308
15.18.3 RECENT DEVELOPMENT 308
15.19 PHARMALOGIC HOLDINGS CORP 309
15.19.1 COMPANY SNAPSHOT 309
15.19.2 PRODUCT PORTFOLIO 309
15.19.3 RECENT DEVELOPMENT 309
15.20 SHINE TECHNOLOGIES, LLC 310
15.20.1 COMPANY SNAPSHOT 310
15.20.2 PRODUCT PORTFOLIO 310
15.20.3 RECENT DEVELOPMENT 310
15.21 SIEMENS HEALTHCARE GMBH 311
15.21.1 COMPANY SNAPSHOT 311
15.21.2 REVENUE ANALYSIS 311
15.21.3 PRODUCT PORTFOLIO 312
15.21.4 RECENT DEVELOPMENT 312
16 QUESTIONNAIRE 313
17 RELATED REPORTS 316

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.